An efficient rHSV-based complementation system for the production of multiple rAAV vector serotypes

Gene Therapy

Volumn 16, Issue 2, 2009, Pages 229-239

  Kang, W ^a   Wang, L ^a   Harrell, H ^a   Liu, J ^a   Thomas, D L ^a   Mayfield, T L ^a   Scotti, M M ^a   Ye, G J ^a   Veres, G ^a   Knop, D R ^a  

^a APPLIED GENETIC TECHNOLOGIES CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; CAP PROTEIN; DEOXYRIBONUCLEASE; GREEN FLUORESCENT PROTEIN; HELICASE; HELICASE 2; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL LINE; CELL STRAIN HEK293; CLINICAL EFFECTIVENESS; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; GENE CASSETTE; GENE CONSTRUCT; GENETIC COMPLEMENTATION; GENETIC TRANSFECTION; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IN VIVO STUDY; INVERTED TERMINAL REPEAT; LARGE SCALE PRODUCTION; MALE; MAMMAL CELL; MIXED INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SEROTYPE; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE; VIRUS RECOMBINANT; VIRUS STRAIN; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; DEPENDOPARVOVIRUS; GENE TRANSFER; GENE VECTOR; GENETIC RECOMBINATION; GENETICS; ISOLATION AND PURIFICATION; PROCEDURES; VIRUS CULTURE; WESTERN BLOTTING;

ADENO-ASSOCIATED VIRUS; ANIMALIA; HUMAN HERPESVIRUS 1; MUS;

ALPHA 1-ANTITRYPSIN; ANIMALS; BLOTTING, WESTERN; CELL LINE; DEPENDOVIRUS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; HUMANS; MALE; MICE; MICE, INBRED C57BL; RECOMBINATION, GENETIC; TRANSFECTION; VIRUS CULTIVATION;

EID: 60449087086     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2008.158     Document Type: Article

References (60)

1. Hermonat PL, Muzyczka N. Use of adeno-associated virus as a mammalian DNA cloning vector: Transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci USA 1984; 81: 6466-6470.
2. Tratschin JD, West MH, Sandbank T, Carter BJ. A human parvovirus, adeno-associated virus, as a eukaryotic vector: Transient expression and encapsidation of the prokaryotic gene for chloramphenicol acetyltransferase. Mol Cell Biol 1984; 4: 2072-2081.
3. Muzyczka N, Berns KI. Parvoviridae: The viruses and their replication. In: Knipe DM, Howley PM (eds). Fields Virology, 4th edn. Lippincott, Williams and Wilkins: New York, NY, 2001, pp 2327-2360.
4. Kotin RM, Siniscalco M, Samulski RJ, Zhu XD, Hunter L, Laughlin CA et al. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 1990; 87: 2211-2215.
5. Kotin RM, Menninger JC, Ward DC, Berns KI. Mapping and direct visualization of a region-specific viral DNA integration site on chromosome 19q13-qter. Genomics 1991; 10: 831-834.
6. Samulski RJ, Zhu X, Xiao X, Brook JD, Housman DE, Epstein N et al. Targeted integration of adeno-associated virus (AAV) into human chromosome 19 [published erratum appears in EMBO J 1992; 11: 1228]. EMBO J 1991; 10: 3941-3950.
7. Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A et al Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000; 24: 257-261.
8. Jiang H, Pierce GF, Ozelo MC, de Paula EV, Vargas JA, Smith P et al Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol Ther 2006; 14: 452-455.
9. Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: An open label, phase I trial. Lancet 2007; 369: 2097-2105.
10. Worgall S, Sondhi D, Hackett NR, Kosofsky B, Kekatpure MV, Neyzi N et al. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther 2008; 19: 463-474.
11. Stedman H, Wilson JM, Finke R, Kleckner AL, Mendell J. Phase I clinical trial utilizing gene therapy for limb girdle muscular dystrophy: α-, β-, γ-, or Δ-sarcoglycan gene delivered with intramuscular instillations of adeno-associated vectors. Hum Gene Ther 2000; 11: 777-790.
12. Tebbutt SJ. Technology evaluation: AAV-CFTR vector, targeted genetics. Curr Opin Mol Ther 1999; 1: 524-529.
13. http://www.clinicaltrials.gov/
14. Brantly ML, Spencer LT, Humphries M, Conlon TJ, Spencer CT, Poirier A et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alpha1-antitrypsin (AAT) vector in AAT-deficient adults. Hum Gene Ther 2006; 17: 1177-1186.
15. Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol 1992; 158: 97-129.
16. Samulski RJ, Srivastava A, Berns KI, Muzyczka N. Rescue of adeno-associated virus from recombinant plasmids: Gene correction within the terminal repeats of AAV. Cell 1983; 33: 135-143.
17. Berns KI. The Parvoviruses. Plenum Press: New York, 1984.
18. Chejanovsky N, Carter BJ. Mutagenesis of an AUG codon in the adeno-associated virus rep gene: Effects on viral DNA replication. Virology 1989; 173: 120-128.
19. Samulski RJ, Chang LS, Shenk T. A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication. J Virol 1987; 61: 3096-3110.
20. Chejanovsky N, Carter BJ. Mutation of a consensus purine nucleotide binding site in the adeno-associated virus rep gene generates a dominant negative phenotype for DNA replication. J Virol 1990; 64: 1764-1770.
21. Huang MM, Hearing P. Adenovirus early region 4 encodes two gene products with redundant effects in lytic infection. J Virol 1989; 63: 2605-2615.
22. Samulski RJ, Shenk T. Adenovirus E1B 55-Mr polypeptide facilitates timely cytoplasmic accumulation of adeno-associated virus mRNAs. J Virol 1988; 62: 206-210.
23. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72: 2224-2232.
24. Clark KR. Recent advances in recombinant adeno-associated virus vector production. Kidney Int 2002; 61s: 9-15.
25. Qiao C, Li J, Skold A, Zhang X, Xiao X. Feasibility of generating adeno-associated virus packaging cell lines containing inducible adenovirus helper genes. J Virol 2002; 76: 1904-1913.
26. Clark KR, Voulgaropoulou F, Fraley DM, Johnson PR. Cell lines for the production of recombinant adeno-associated virus. Hum Gene Ther 1995; 6: 1329-1341.
27. Grimm D, Kern A, Rittner K, Kleinschmidt JA. Novel Tools for production and purification of recombinant adeno-associated virus vectors. Hum Gene Ther 1998; 9: 2745-2760.
28. Zolotukhin S, Potter M, Zolotukhin I, Sakai Y, Loiler S, Fraites Jr TJ et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 2002; 28 158-167.
29. Buller RML, Janik JE, Sebring ED, Rose JA. Herpes simplex virus types 1 and 2 completely help adenovirus-associated virus replication. J Virol 1981; 40: 241-247.
30. Weindler FW, Heilbronn R. A Subset of herpes simplex virus replication genes provides helper functions for productive adeno-associated virus replication. J Virol 1991; 65: 2476-2483.
31. Conway JE, ap Rhys CMJ, Zolotukhin I, Zolotukhin S, Muzyczka N, Hayward GS et al. High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV2 Rep and Cap. Gene Therapy 1999; 6: 986-993.
32. Conway JE, Zolotukhin S, Muzyczka N, Hayward GS, Byrne BJ. Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing rep and cap. J Virol 1997; 71: 8780-8789.
33. Mistry AR, De Alwis M, Feudner E, Ali RR, Thrasher AJ. High-titer stocks of adeno-associated virus from replicating amplicons and herpes vectors. Methods Mol Med 2002; 69: 445-460.
34. Wustner JT, Arnold S, Lock M, Richardson JC, Himes VB, Kurtzman G et al. Production of recombinant adeno-associated type 5 (rAAV5) vectors using recombinant herpes simplex viruses containing rep and cap. Mol Ther 2002; 6: 510-518.
35. Feudner E, de Alwis M, Thrasher AJ, Ali RR, Fauser S. Optimization of recombinant adeno-associated virus production using an herpes simplex virus amplicon system. J Virol Methods 2001; 96: 97-105.
36. Zhang X, de Alwis M, Hart SL, Fitzke FW, Inglis SC, Boursnell MEG et al. High-titer recombinant adeno-associated virus production from replicating amplicons and herpes vectors deleted for glycoprotein H. Hum Gene Ther 1999; 10: 2527-2537.
37. Booth MJ, Mistry A, Li X, Thrasher A, Coffin RS. Transfection-free and scalable recombinant AAV vector production using HSV/AAV hybrids. Gene Therapy 2004; 11: 829-837.
38. Toublanc E, Benraiss A, Bonnin D, Blouin V, Brument N, Cartier N et al. Identification of a replication-defective herpes simplex virus for recombinant adeno-associated virus type 2 (rAAV2) particle assembly using stable producer cell lines. J Gene Med 2004; 6: 555-564.
39. Sollerbrant K, Elmén J, Wahlestedt C, Acker J, Leblois-Prehaud H, Latta-Mahieu M et al. A novel method using baculovirus-mediated gene transfer for production of recombinant adeno-associated virus vectors. J Gen Virol 2001; 82: 2051-2060.
40. Urabe M, Ding C, Kotin RM. Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Gene Ther 2002; 13 1935-1943.
41. Meghrous J, Aucoin MG, Jacob D, Chahal PS, Arcand N, Kamen AA. Production of recombinant adeno-associated viral vectors using a baculovirus/insect cell suspension culture system: From shake flasks to a 20-L bioreactor. Biotechnol Prog 2005; 21: 154-160.
42. Kohlbrenner E, Aslanidi G, Nash K, Shklyaev S, Campbell-Thompson M, Byrne BJ et al. Successful production of pseudotyped rAAV vectors using a modified baculovirus expression system. Mol Ther 2005; 12: 1217-1225.
43. Allen JM, Debelak DJ, Reynolds TC, Miller AD. Identification and elimination of replication-competent adeno-associated virus (AAV) that can arise by nonhomologous recombination during AAV vector production. J Virol 1997; 71: 6816-6822.
44. Ogasawara Y, Urabe M, Kogure K, Kume A, Colosi P, Kurtzman GJ et al Efficient production of adeno-associated virus vectors using split-type helper plasmids. Jpn J Cancer Res 1999; 90: 476-483.
45. Rice SA, Knipe DM. Genetic evidence for two distinct transactivation functions of the herpes simplex virus α protein ICP27. J Virol 1990; 64: 1704-1715.
46. Knop DR, Harrell H. Bioreactor production of recombinant herpes simplex virus vectors. Biotechnol Prog 2007; 23: 715-721.
47. Li J, Samulski RJ, Xiao X. Role for highly regulated rep gene expression in adeno-associated virus vector production. J Virol 1997; 71: 5236-5243.
48. Ogasawara Y, Urabe M, Ozawa K. The use of heterologous promoters for adeno-associated virus (AAV) protein expression in AAV vector production. Microbiol Immunol 1998; 42: 177-185.
49. Mendelson E, Trempe JP, Carter BJ. Identification of the transacting rep proteins of adeno-associated virus by antibodies to a synthetic oligopeptide. J Virol 1986; 60: 823-832.
50. Trempe JP, Mendelson E, Carter BJ. Characterization of adeno-associated virus rep proteins in human cells by antibodies raised against rep expressed in Escherichia coli. Virology 1987; 161: 18-28.
51. Buller RML, Straus SE, Rose JA. Mechanism of host restriction of adenovirus-associated virus replication in African green monkey kidney cells. J Gen Virol 1970; 43: 663-672.
52. Collaco RF, Cao X, Trempe JP. A Helper virus-free packaging system for recombinant adeno-associated virus vectors. Gene 1999; 238: 397-405.
53. Ye G et al. A novel herpes simplex virus helper based production of adeno-associated virus vectors for treatment of retinal angiogenesis. Mol Ther 2006; 13 (Suppl 1s): 194 (Abstract 503).
54. Aubert M, Blaho JA. The herpes simplex virus type 1 regulatory protein ICP27 is required for the prevention of apoptosis in infected human cells. J Virol 1999; 73: 2803-2813.
55. Sanfilippo CM, Chirimuuta FNW, Blaho JA. Herpes simplex virus type 1 immediate-early gene expression is required for the induction of apoptosis in human epithelial HEp-2 cells. J Virol 2004; 78: 224-239.
56. Sanfilippo CM, Blaho JA. ICP0 gene expression is a herpes simplex virus type 1 apoptotic trigger. J Virol 2006; 80: 6810-6821.
57. DeFilippis RA, Goodwin EC, Wu L, DiMaio D. Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells. J Virol 2003; 77: 1551-1563.
58. Conway JE. Herpes simplex virus type I based systems for the large-scale production of recombinant adeno-associated virus type-2 vectors. A dissertation. 2001, John Hopkins University.
59. Clark KR, Voulgaropoulou F, Johnson PR. A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors. Gene Therapy 1996; 3: 1124-1132.
60. Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Therapy 1999; 6: 973-985.